Regulatory

March 26, 2024

First gastroesophageal cancer patients enrolled in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025

Solna, Sweden, March 26, 2024. Affibody AB (“Affibody”) today announced that the first patients with gastroesophageal cancer have been dosed in a Phase 2 clinical basket study of the...

Read more

Regulatory

March 11, 2024

Affibody’s Partner ACELYRIN Announces Positive Top-line Results for Izokibep in Psoriatic Arthritis and Long-Term Clinical Benefits in Hidradenitis Suppurativa

Phase 2b/3 psoriatic arthritis clinical trial met the primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance. Robust responses were achieved for ACR70, PASI100, ACR50/PASI100,...

Read more

Regulatory

December 20, 2023

Affibody’s Licensee Rallybio Announces Preliminary Phase 1 MAD Data for RLYB116

Solna, Sweden, December 20, 2023. Affibody’s licensee Rallybio Corporation (Rallybio) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected...

Read more

Regulatory

November 27, 2023

Affibody’s Partner ACELYRIN Provides Update on Izokibep Clinical Development Program

Solna, Sweden, November 27, 2023. Affibody’s partner ACELYRIN, INC. (“ACELYRIN”) today provided an update on its izokibep clinical development program, including the ongoing global Phase 2b/3 trial in psoriatic...

Read more

Regulatory

October 3, 2023

Affibody appoints Peter Zerhouni as CFO

Solna, Sweden, October 3, 2023. Affibody AB (“Affibody”) today announced that Peter Zerhouni has been appointed Chief Financial Officer (CFO) of the Company. Peter Zerhouni joined Affibody as Chief...

Read more

Regulatory

September 11, 2023

Affibody’s Partner ACELYRIN Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa

• The primary endpoint of HiSCR75 at week 16 did not meet statistical significance in the Non-Responder Imputation (NRI) primary analysis. • HiSCR75 did meet statistical significance at week 16...

Read more

Regulatory

August 30, 2023

Data demonstrating that Affibody’s PET imaging agent ABY-025 can be used to predict therapeutic response will be presented at EANM

Solna, Sweden, August 30, 2023. Affibody AB (“Affibody”) today announced the presentation of data from patients in a clinical study of the PET imaging agent 68Ga-ABY-025 for non-invasive quantification...

Read more

Regulatory

June 30, 2023

First ten HER2-low patients dosed in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025

Solna, Sweden, June 30, 2023. Affibody AB (“Affibody”) today announced that the first ten patients have been dosed in a Phase 2 clinical basket study of the PET imaging...

Read more

Regulatory

April 11, 2023

Positive Long-term Results with Izokibep in Psoriatic Arthritis

• Affibody’s partner ACELYRIN, INC today announced 46 weeks Phase 2 data where izokibep demonstrated high levels of response across psoriatic arthritis disease manifestations.• Long-term data build on statistically...

Read more